Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

The AVT16-GL-C01 multicenter study has a double-blind parallel design with 2 arms. Participants will receive either AVT16 or Entyvio, and all participants will be followed to determine efficacy of the ...

The Biosimilar Red Tape Elimination Act aims to increase the market share of biosimilars. It could drive costs higher.

Biocon Biologics presents new dermatology data from two clinical studies at EADV Congress 2024: Our Bureau, Bengaluru Wednesday, September 25, 2024, 13:40 Hrs [IST] Biocon Biologi ...

Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports ...

PCI Pharma Services Invests Over $365 Million In EU, US Facilities For Clinical And Commercial Supply Of Advanced Drug D ...

PRNewswire/ -- "According to the latest BCC Research study, the demand for "Cell Therapy Biomanufacturing: Global Markets" is ...

Mayo Clinic in Florida has received a grant from the National Institute of Neurological Disorders and Stroke (NIDS) to begin an innovative study that will provide hundreds of patients with amyotrophic ...

PALMOILMAGAZINE, JAKARTA - Due to the increasing difficulty in distinguishing between halal and non-halal products, it is ...

Cerapedics earned FDA approval to expand the use of its spinal fusion biologic, i-Factor P-15, according to a Sept. 24 news release.

Highlights include investment in Philadelphia biotech facility, acquisition of a new pharma device assembly and packaging facility near Dublin ...

Capricor Therapeutics shares rose in premarket trading Tuesday after the company said it plans to file a biologics license application for Deramiocel, its Duchenne muscular dystrophy cardiomyopathy ...